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Antithrombin Population Pharmacokinetics in
Pediatric Ventricular Assist Device Patients
Brady S. Moffett, PharmD, MPH1,2; Marc Anders, MD2; Timothy Humlicek, PharmD1;
Marianne Galati, MSW, MLIS3; Jun Teruya, MD, DSc2,4; Iki Adachi, MD2,5; Sebastian Tume, MD2

Objectives: Describe the pharmacokinetics of antithrombin in pediatric patients undergoing ventricular assist device therapy and provide dosing recommendations for antithrombin in this population.
Design: A retrospective population pharmacokinetic study was
designed.
Setting: Large tertiary care children’s hospital Subject inclusion
criteria consisted of less than 19 years old.
Patients: Subjects less than 19 years old undergoing therapy with a
HeartWare ventricular assist device (HeartWare, Framingham, MA)
or Berlin EXCOR ventricular assist device (Berlin GmbH, Berlin,
Germany), who received a dose of antithrombin with a postdose
antithrombin activity level from January 1, 2011, to June 30, 2017.
Interventions: Population pharmacokinetic analysis and simulation using NONMEM v.7.4 (Icon, PLC, Dublin, Ireland).
Measurements and Main Results: A total of 41 patients met study
criteria (median age, 5.8 years [interquartile range, 1.6–9.9 yr]),
and 53.7% underwent therapy with the pulsatile Berlin EXCOR
pediatric ventricular assist device (Berlin Heart GmbH, Berlin,
Germany). All patients received unfractionated heparin continuous infusion at a mean ± sd dose of 29 ± 14 U/kg/hr. A total of
181 antithrombin doses (44.1 ± 24.6 U/kg/dose) were included,
and baseline antithrombin activity levels were 77 ± 12 U/dL.
Antithrombin activity levels were drawn a median 19.9 hours (interquartile range, 8.8–41.6 hr) after antithrombin dose. A one-comDepartment of Pharmacy, Texas Children’s Hospital, Houston, TX.
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partment proportional error model best fit the data, with allometric
scaling of fat-free mass providing a better model fit than actual
body weight. Unfractionated heparin and baseline antithrombin
were identified as significant covariates. A 50 U/kg dose of antithrombin had a simulated half-life 13.2 ± 6.6 hours.
Conclusions: Antithrombin should be dosed on fat-free mass in
pediatric ventricular assist device patients. Unfractionated heparin dose and baseline antithrombin activity level should be considered when dosing antithrombin in pediatric ventricular assist
device patients. (Pediatr Crit Care Med 2019; 20:1157–1163)
Key Words: antithrombin; NONMEM; pediatrics; population
pharmacokinetics; ventricular assist device

A

nticoagulation management in pediatric patients
undergoing therapy with a ventricular assist device
(VAD) is challenging and is compounded by the limited data for optimal pharmacotherapy (1–7). A variety of
strategies for management of hemostasis and anticoagulation
in the VAD population are often used based upon individual
patient characteristics, institutional protocols, type of VAD,
and overall patient goals (8). Similar to patients treated with
extracorporeal membrane oxygenation, the pharmacokinetic
disposition of many medications in the pediatric VAD population may be altered due to changes in blood volume, end-organ
dysfunction, postoperative inflammation, characteristics of
the VAD circuit, and patient circulatory pathophysiology (9).
Use of human-derived antithrombin is a pharmacotherapeutic intervention for patients receiving high dose unfractionated
heparin (UFH) therapy who are not achieving anticoagulation
goals (10–12). The role of antithrombin in the coagulation cascade involves inactivation of factor IIa (thrombin) and factor Xa
in the presence of UFH (13). Antithrombin is an endogenous
protein, and high dose UFH can contribute to depletion of antithrombin resulting in diminished efficacy of UFH, undesirable
alterations in markers of hemostasis, and potential increase in
patient thrombosis risk (14). Alternatively, supplementation of
antithrombin is commonly used to improve the efficacy of UFH,
resulting in lower UFH doses while maintaining goal anticoagulation markers (15).
www.pccmjournal.org
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UFH is commonly used as an anticoagulation strategy in
the pediatric VAD population due to the large substrate for
thrombus formation in comparison to patient size and the
acuity of the patient population, particularly in the early postoperative period (6, 16–18). Bleeding complications in the VAD
population can be frequent and potentially life-threatening, and
close management of anticoagulation strategies, including strategies for antithrombin supplementation, is necessary (19–21).
At our institution, antithrombin has been supplemented in
pediatric VAD patients undergoing therapy with the HeartWare
VAD (HeartWare, Framingham, MA) and the Berlin Heart
EXCOR VAD (Berlin Heart GmbH, Berlin, Germany). There
are no pharmacokinetic data to support dosing of antithrombin in the pediatric VAD population and the potential for altered disposition of antithrombin in this patient population
is significant. The objective of this study is to characterize the
pharmacokinetic disposition of antithrombin in the pediatric
VAD population and derive dosing recommendations for antithrombin use in the pediatric VAD population.

MATERIALS AND METHODS

dose (U/hr), serum creatinine (mg/dL), urine output over the 12
hours prior to the antithrombin activity (mL), platelets (/mm3),
hematocrit (%), antithrombin dose (U), and antithrombin activity (U/dL). Fat-free mass (FFM) was calculated for each patient
as well as body surface area (22, 23) (Appendix I, Supplemental
Digital Content 1, http://links.lww.com/PCC/B27). The methodology for analysis of antithrombin activity levels at our institution has been previously reported and included the use of
the STA-R analyzer using the STA-Rotachrom antithrombin kit
(Diagnostica Stago, Asnieres, France) (24).
Descriptive Analysis
Descriptive statistical methods using percentages, mean, sd,
median and range, for normally and nonnormally distributed
data were used as appropriate, as was data visualization. Statistical analyses were performed using Excel 2013 (Microsoft
Corp, Redmond, WA).
Pharmacokinetic Analysis
NONMEM v.7.4 (Icon, PLC, Dublin, Ireland) and PDx-Pop
5.2 (Icon, PLC) using first-order conditional estimation with
interaction were used for the population pharmacokinetic
analysis. Interindividual variability (IIV) was exponentially
modeled. A base model, with no covariates, was initially developed based upon prior literature and graphing antithrombin
activity versus time after dose (Fig. 1). Baseline activity levels
(BASE) were included in the error model to account for endogenous production of antithrombin (25). One and two compartment models, with additive, exponential, proportional,
and proportional and additive error structures were evaluated.

The study was approved by the Baylor College of Medicine
and Affiliated Institutions Institutional Review Board. A retrospective descriptive population pharmacokinetic study was
designed, and patients were identified by querying the hospital
electronic medical record system from January 1, 2011, to June
30, 2017, for administration of human-derived antithrombin (Thrombate; Grifols USA, LLC, Clayton, NC). Patients
were included in the study if they were less than 19 years
old, underwent therapy with a either a pulsatile Berlin Heart
EXCOR pediatric VAD (Berlin
Heart GmbH) or nonpulsatile HeartWare VAD, received
a dose of antithrombin while
undergoing VAD therapy, had
a baseline antithrombin activity level, and had at least
one antithrombin activity level
drawn after antithrombin administration while undergoing
VAD therapy. Patient data were
excluded if they received fresh
frozen plasma or cryoprecipitate during antithrombin
therapy. The first antithrombin concentration after a
dose was included, and subsequent concentrations were
included if they were less than
or equal to the first postdose
concentration.
Data collection included as
follows: male (M), patient age
in years (AGEYRS), weight (kg),
height (cm), type of VAD (pul- Figure 1. Antithrombin activity (U/dL) versus time after antithrombin administration (hr). A large portion of the
satile vs nonpulsatile), UFH
antithrombin activity was sampled in the 48 hr after a dose.
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TABLE 1.

Demographic Variables

Category (n = 41)

Value

Male (%)

43.9

Age, yr, median (IQR)

5.8 (1.6–9.9)

Height, cm, median (IQR)

114 (78–132)

Weight, kg, median (IQR)

19.5 (8.6–27.7)

Body surface area, m2, mean (sd)

0.86 ± 0.54

Fat-free mass, kg, median (IQR)

16.0 (7.0–22.9)

Hematocrit (%), mean (sd)

30.9 ± 3.9

Platelet (count/μL), mean (sd)

244 ± 127

Serum creatinine (mg/dL), mean (sd)

0.42 ± 0.32

Urine output over previous 12 hr (mL),
mean (sd)

593 ± 394
3.1 ± 2.0

Urine output over previous 12 hr
(mL/kg/hr), mean (sd)
IQR = interquartile range.

Covariates were visually evaluated against pharmacokinetic
variables for potential inclusion in the population pharmacokinetic model. After inclusion of a covariate, a reduction of
greater than 3.84 in the objective function value (OFV) was
considered statistically significant. After individual covariate
analysis, a full model, containing all statistically significant
covariates, was developed. A covariate was retained for the
final model if the OFV increased by greater than 10.83 (a significance level of p < 0.001 at one degree of freedom) when
an individual covariate was removed from the full model (26).
Bootstrap simulations were performed (n = 1,000) on the final
model with calculation of 95% CIs.
Scatter plots of dependent variables versus population predicted (PRED) and individual predicted antithrombin activity
levels and conditional weighted residuals versus PRED and
time after dose were developed for the final model to evaluate
bias and determine goodness of fit (27) (Figs. 2–5).
Based upon the final model, a simulation was performed with
10,000 replications to derive dosing recommendations. A virtual
patient for the simulation was developed from mean covariate
values in the dataset based upon the included covariates in the final
model. A dose of 50 U/kg infused over 15 minutes was simulated,
TABLE 2.

based upon previously published data, and antithrombin activity
levels were simulated at 1-hour post-infusion, 6 hours, 12 hours,
and 24 hours (28). Simulated clearance, volume of distribution
(VD), and half-life were calculated from the simulation dataset to
help provide dosing and monitoring recommendations.

RESULTS
Demographics
A total of 41 patients met study criteria and 53.7% (n = 22)
underwent therapy with the Berlin EXCOR VAD (pulsatile),
the rest with the HeartWare VAD (nonpulsatile). Demographic
information was summarized (Table 1). All patients received
UFH continuous infusion at a mean dose of 29 ± 14 U/kg/hr.
Patients received a total of 181 doses of antithrombin infused
over 15 minutes at a mean dose of 798 ± 720 U (44.1 ± 24.6 U/
kg/dose). Baseline antithrombin activity levels were a mean
77 ± 12 U/dL prior to an antithrombin dose. In total, 475 postdose antithrombin activity levels (median 6 [interquartile
range (IQR) 3–14] per patient) were sampled at a median 19.9
hours (IQR, 8.8–41.6 hr) after an antithrombin dose and were
a median 89 U/dL (IQR, 79–106 U/dL) (Fig. 1).
Pharmacokinetic Modeling
Initial noncompartmental pharmacokinetic investigations
into the data elucidated estimates of VD to be median 2.67 dL/
kg (IQR, 1.1–5.9 dL/kg) and clearance of median 2.35 dL/hr
(IQR, 0.62–6.89 dL/hr). Population pharmacokinetic modeling identified a one-compartment proportional error model
fit the data (had the lowest OFV) with IIV modeled exponentially. Weight and FFM were added to the base model with allometric scaling on clearance (exponent 0.75) and VD (exponent
1), and the model with FFM had the lowest OFV (Supplemental Table 1, Supplemental Digital Content 2, http://links.
lww.com/PCC/B28). The model with FFM was then used for
further analysis of individual covariates.
Covariates which resulted in a significant (> 3.84) decrease
in OFV on clearance included UFH and BASE antithrombin
activity level, while AGEYRS and the use of the Berlin Heart
EXCOR (pulsatile) resulted in significant changes in the OFV
when evaluating VD. During the backward stepwise removal
of covariates, only UFH and BASE remained statistically significant (change in OFV > 10.83), and remained the only
two covariates (other than FFM) in the final model (Table 2).

Final Pharmacokinetic Model
Interindividual
Variability (%)

Model (n = 41)

 FFM 
CL = 2.75 × 
 70 

0.75

 BASE 
×
 76 

 FFM 
VD = 71.5 × 
 70 

2.88

 UFH + 1
×
 400 

0.1
11

Residual
Variability (%)

42.7

11.4

21.1

BASE = baseline antithrombin activity (U/dL), CL = clearance (dL/hr), FFM = fat-free mass (kg), UFH = unfractionated heparin (U/hr), VD = volume of
distribution (dL).
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Simulation
A virtual patient was developed from the mean covariate values in the dataset
(weight = 19.5, FFM = 16 kg,
BASE (baseline antithrombin
activity) = 77 U/dL, UFH =
29 U/kg/hr) who received a 50
U/kg bolus (based on FFM).
The resultant simulated concentrations at 1, 6, 12, and
24 hours after the dose were
124 ± 11, 111 ± 9, 101 ± 9, and
89 ± 8 U/dL, respectively. Simulated pharmacokinetic values
were as follows: clearance was
0.05 ± 0.02 dL/kg/hr, VD was
0.85 ± 0.18 dL/kg, and half-life
was calculated to be 13.2 ± 6.6
hours.

DISCUSSION
This is the first evaluation
of antithrombin population
pharmacokinetics in the pediatric VAD population. Insights
into the pharmacokinetic profile include the lack of effect
of VAD type on antithrombin
pharmacokinetics and the use
of FFM to more accurately describe clearance and VD. The
use of FFM in this patient
population is significant as
the presence of obesity in the
pediatric patient population
approaches 20% of 2–18 year
olds (29). The use of FFM to
dose medications in this patient population can potentially be extrapolated to other
medications used in pediatric
VAD patients, such UFH,
which require lower doses per
body weight in obese patients
as compared with nonobese
patients (30, 31). FFM should
be used to dose antithrombin in the pediatric VAD
Figure 3. Dependent variables versus individual predicted. There is good agreement around the line of unity
population.
demonstrating model fit.
We have identified two additional covariates, baseline
Diagnostic plots demonstrated good fit around lines of unity and antithrombin activity level (BASE) and dose of UFH, which
no apparent bias (Figs. 2–5). Bootstrap analysis was performed on affect the clearance of antithrombin. The clearance of antithe final model with a 95.2% success rate (Supplemental Table 2, thrombin in the pediatric VAD population is greater than what
Supplemental Digital Content 3, http://links.lww.com/PCC/B29). has been previously reported in adult and pediatric patients
Figure 2. Dependent variables versus population predicted. There is good agreement around the line of unity
demonstrating model fit.
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identified with VAD patients,
resulted in the higher clearance
values. Also, the model developed from the prior investigation demonstrated an additive
effect of the use of UFH on
clearance, while the model
we have developed in the present study has a multiplicative
effect of UFH on clearance
(24). The relationship between UFH and antithrombin is complex, as increased
doses of UFH can increase
the clearance of antithrombin,
yet supplementation of antithrombin has been shown to
decrease UFH requirements
while maintaining goal markers of anticoagulation, such as
the activated partial thromboplastin time (11, 12, 32, 33). We
did not incorporate anticoagulation endpoints into our analFigure 4. Conditional weighted residuals versus population predicted concentrations. No apparent bias is noted
ysis; however, it is evident that
in the figure demonstrating model fit.
evaluation of UFH dose prior
to antithrombin dosing and
monitoring in the pediatric
VAD population is necessary.
Estimates for VD were remarkably similar in this analysis of the pediatric VAD
population (71.5 dL) as compared with the pediatric nonVAD population (67.9 dL) (24).
Both of these values are somewhat higher than the estimates
reported from a noncompartmental pharmacokinetic analysis of antithrombin in the
adult population (45 dL) (34).
The difference in VD is likely
due to changes in body habitus
associated with maturation of
pediatric patients (35). It is
clear from our analysis that the
pediatric VAD population has
altered antithrombin pharmacokinetic values, particularly
on clearance, compared with
Figure 5. Conditional weighted residuals versus time after antithrombin administration (hr). No apparent bias is
noted in the figure demonstrating model fit.
adult or pediatric non-VAD
patient populations.
and is approximately three times higher than those we have
We simulated a dose of 50 U/kg, which has been previously
previously identified in the pediatric non-VAD population reported as an empiric dose in the pediatric patient popula(2.75 dL/hr vs 0.917 dL/hr) (24). We can speculate that the tion (28). We had previously estimated a dose of approximately
VAD circuit, and the associated coagulopathies that have been 60 U/kg in the pediatric non-VAD population to attain an
Pediatric Critical Care Medicine
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antithrombin activity level of 120% in patients with a baseline
of 60 U/dL and receiving 34 U/kg/hr of UFH (24). We present the data from the simulation as a guide to antithrombin
dosing in this patient population, as individual patient cases
will undoubtedly require alterations in dosing and monitoring strategies. The goal of antithrombin activity levels in pediatric VAD patients are not absolutely defined, and the normal
values of antithrombin activity in pediatric patients are often
considered 85–130% (36). Due to the complexity involved in
VAD anticoagulation, recommendations for specific dosing
and monitoring regimens would be outside the scope of this
article. However, the dose of 50 U/kg appears to be a reasonable empiric dose to achieve antithrombin activity levels that
have been recognized as therapeutic. Monitoring and re-dosing strategies can be evaluated based upon the half-life values
generated and the dose of UFH concomitantly administered.
The dose to be used for a patient should encompass overall patient goals and the analysis we have provided should serve as a
basis for monitoring and dosing of antithrombin.
This is a retrospective review of data, and the limitations associated with this type of study should temper the conclusions
and applications of these data. The data collected were clinical
data, and data such as fluid intake, were unable to be captured.
The indications for antithrombin, such as baseline antithrombin activity, and frequency of monitoring, were under the
purview of the clinician. Prospective analysis, with a defined
sampling strategy, would likely improve the characterization
of the pharmacokinetic estimates we have derived. Prospective
validation of the developed model would also be necessary to
evaluate the recommendations we have provided.
We would like to note that the patient population we evaluated consisted of the HeartWare or Berlin Heart EXCOR
patients (the only VAD patients who received antithrombin
at our institution) and that extrapolation to other VAD types
should only occur with considerable caution. We were unable
to evaluate any patient outcomes with antithrombin supplementation. To fully evaluate the effect of antithrombin in the
pediatric VAD population, outcomes such as bleeding, thrombosis, and circuit life will have to be evaluated.

CONCLUSIONS
This study provides the first insight into the pharmacokinetics
of antithrombin in children with end-stage heart failure supported with VADs. Antithrombin pharmacokinetics appear
to be altered by UFH and the baseline antithrombin activity
levels in pediatric patients undergoing VAD therapy. FFM
appears to be superior to actual body weight for characterization of antithrombin pharmacokinetics and should be used
for replacement dosing. Finally, the characteristics of the VAD
flow pattern and support do not seem to affect antithrombin
pharmacokinetics.
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